Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Tennstedt

Showing results (61-70 of 112) with videos related to

Pageof 12
Sort By:
The Prostate|April 13, 2023
Feasibility, acceptability, and behavioral outcomes of a multimodal intervention for prostate cancer patients: Experience from the MARTINI lifestyle programImke Thederan, Aliaksandra Pott, Alexander Krueger, et al.
Frontiers in Surgery|January 13, 2018
AB0/Rhesus Blood Group Does Not Influence Clinicopathological Tumor Characteristics or Oncological Outcome in Patients Undergoing Radical ProstatectomySu Jung Oh, Philipp Mandel, Felix K H Chun, et al.
World Journal of Urology|October 20, 2011
Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinomaChristian Eichelberg, Sarah Minner, Hendrik Isbarn, et al.
The Aging Male : the Official Journal of the International Society for the Study of the Aging Male|May 7, 2024
Impact of COVID-19 on the time to counseling and treatment of prostate cancerDejan K Filipas, Randi M Pose, Phillip Marks, et al.
Cancer|December 14, 2011
Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinomaSarah Minner, Dorothea Rump, Pierre Tennstedt, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|December 5, 2014
Additional androgen deprivation makes the difference: Biochemical recurrence-free survival in prostate cancer patients after HDR brachytherapy and external beam radiotherapyJonas Schiffmann, Hans Lesmana, Pierre Tennstedt, et al.
Plos One|August 3, 2017
Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancerKathrin Endt, Jens Goepfert, Aurelius Omlin, et al.
The Prostate|August 16, 2022
New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health indexDaniela Terracciano, Evelina La Civita, Alcibiade Athanasiou, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2013
Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancerPhilippe O Gannon, Laurent Lessard, Louis-Mathieu Stevens, et al.
BJU International|April 24, 2012
Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patientsLars Budäus, Hendrik Isbarn, Pierre Tennstedt, et al.
Pageof 12

Showing results (61-70 of 112) with videos related to

Sort By:
Pageof 12
The Prostate|April 13, 2023
Feasibility, acceptability, and behavioral outcomes of a multimodal intervention for prostate cancer patients: Experience from the MARTINI lifestyle programImke Thederan, Aliaksandra Pott, Alexander Krueger, et al.
Frontiers in Surgery|January 13, 2018
AB0/Rhesus Blood Group Does Not Influence Clinicopathological Tumor Characteristics or Oncological Outcome in Patients Undergoing Radical ProstatectomySu Jung Oh, Philipp Mandel, Felix K H Chun, et al.
World Journal of Urology|October 20, 2011
Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinomaChristian Eichelberg, Sarah Minner, Hendrik Isbarn, et al.
The Aging Male : the Official Journal of the International Society for the Study of the Aging Male|May 7, 2024
Impact of COVID-19 on the time to counseling and treatment of prostate cancerDejan K Filipas, Randi M Pose, Phillip Marks, et al.
Cancer|December 14, 2011
Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinomaSarah Minner, Dorothea Rump, Pierre Tennstedt, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|December 5, 2014
Additional androgen deprivation makes the difference: Biochemical recurrence-free survival in prostate cancer patients after HDR brachytherapy and external beam radiotherapyJonas Schiffmann, Hans Lesmana, Pierre Tennstedt, et al.
Plos One|August 3, 2017
Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancerKathrin Endt, Jens Goepfert, Aurelius Omlin, et al.
The Prostate|August 16, 2022
New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health indexDaniela Terracciano, Evelina La Civita, Alcibiade Athanasiou, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2013
Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancerPhilippe O Gannon, Laurent Lessard, Louis-Mathieu Stevens, et al.
BJU International|April 24, 2012
Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patientsLars Budäus, Hendrik Isbarn, Pierre Tennstedt, et al.
Pageof 12